These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 7055978
1. Serum bile acid profiles in cerebrotendinous xanthomatosis. Beppu T, Seyama Y, Kasama T, Serizawa S, Yamakawa T. Clin Chim Acta; 1982 Feb 05; 118(2-3):167-75. PubMed ID: 7055978 [Abstract] [Full Text] [Related]
2. A case of cerebrotendinous xanthomatosis: effects of ursodeoxycholic acid administration on serum bile acids and cholestanol. Kimura S, Beppu T, Kugai N, Koide Y, Fujita T, Iida K, Yamashita N, Yamashita K, Seyama Y. Jpn J Med; 1982 Jul 05; 21(3):210-5. PubMed ID: 7143816 [Abstract] [Full Text] [Related]
3. Quantitative determination of individual non-sulfated bile acids and sulfated lithocholic acid in serum by mass fragmentography. Beppu T, Seyama Y, Kasama T, Yamakawa T. J Biochem; 1981 Jun 05; 89(6):1963-73. PubMed ID: 7287668 [Abstract] [Full Text] [Related]
4. Cerebrotendinous xanthomatosis: reduced serum 26-hydroxycholesterol. Javitt NB, Kok E, Cohen B, Burstein S. J Lipid Res; 1982 May 05; 23(4):627-30. PubMed ID: 7097127 [Abstract] [Full Text] [Related]
5. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis. Salen G, Shefer S, Tint GS. Gastroenterology; 1984 Aug 05; 87(2):276-83. PubMed ID: 6735073 [Abstract] [Full Text] [Related]
6. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Batta AK, Salen G, Tint GS. Metabolism; 2004 May 05; 53(5):556-62. PubMed ID: 15131757 [Abstract] [Full Text] [Related]
7. Quantitative determination of bile acid glucuronides in serum by mass fragmentography. Takikawa H, Otsuka H, Beppu T, Seyama Y, Yamakawa T. J Biochem; 1982 Oct 05; 92(4):985-98. PubMed ID: 7174649 [Abstract] [Full Text] [Related]
8. Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. Koopman BJ, Wolthers BG, van der Molen JC, Waterreus RJ. Clin Chim Acta; 1985 Oct 31; 152(1-2):115-22. PubMed ID: 4053393 [Abstract] [Full Text] [Related]
9. Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. Salen G, Shefer S, Tint GS, Nicolau G, Dayal B, Batta AK. J Clin Invest; 1985 Aug 31; 76(2):744-51. PubMed ID: 4031069 [Abstract] [Full Text] [Related]
10. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. Berginer VM, Salen G, Shefer S. N Engl J Med; 1984 Dec 27; 311(26):1649-52. PubMed ID: 6504105 [Abstract] [Full Text] [Related]
11. Biochemical studies of inherited diseases related to abnormal cholesterol metabolism. I. High-performance liquid chromatographic analysis of bile alcohol glucuronides in cerebrotendinous xanthomatosis. Ohshima A, Kuramoto T, Hoshita T. Biol Pharm Bull; 1994 May 27; 17(5):721-3. PubMed ID: 7920441 [Abstract] [Full Text] [Related]
12. Increased formation of ursodeoxycholic acid in patients treated with chenodeoxycholic acid. Salen G, Tint GS, Eliav B, Deering N, Mosbach EH. J Clin Invest; 1974 Feb 27; 53(2):612-21. PubMed ID: 11344576 [Abstract] [Full Text] [Related]
13. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis. Clarenbach JJ, Lindenthal B, Dotti MT, Federico A, Kelleher JK, von Bergmann K. Metabolism; 2005 Mar 27; 54(3):335-44. PubMed ID: 15736111 [Abstract] [Full Text] [Related]
14. Serum concentrations of bile acid glucuronides in hepatobiliary diseases. Takikawa H, Otsuka H, Beppu T, Seyama Y, Yamakawa T. Digestion; 1983 Mar 27; 27(4):189-95. PubMed ID: 6653918 [Abstract] [Full Text] [Related]
15. Reduction of urinary bile alcohol excretion and serum cholestanol in patients with cerebrotendinous xanthomatosis after oral administration of deoxycholic acid. Wolthers BG, van der Molen JC, Walrecht H, Hesselmans LF. Clin Chim Acta; 1990 Dec 14; 193(3):113-8. PubMed ID: 2282689 [Abstract] [Full Text] [Related]
16. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. Koopman BJ, Wolthers BG, van der Molen JC, Nagel GT, Kruizinga W. Biochim Biophys Acta; 1987 Feb 14; 917(2):238-46. PubMed ID: 3801500 [Abstract] [Full Text] [Related]
17. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands. Koopman BJ, Wolthers BG, van der Molen JC, van der Slik W, Waterreus RJ, van Spreeken A. J Inherit Metab Dis; 1988 Feb 14; 11(1):56-75. PubMed ID: 3128689 [Abstract] [Full Text] [Related]
18. Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis. An in vivo study. Björkhem I, Fausa O, Hopen G, Oftebro H, Pedersen JI, Skrede S. J Clin Invest; 1983 Jan 14; 71(1):142-8. PubMed ID: 6848555 [Abstract] [Full Text] [Related]
19. Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography. Wolthers BG, Volmer M, van der Molen J, Koopman BJ, de Jager AE, Waterreus RJ. Clin Chim Acta; 1983 Jun 30; 131(1-2):53-65. PubMed ID: 6883710 [Abstract] [Full Text] [Related]
20. Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. Batta AK, Shefer S, Batta M, Salen G. J Lipid Res; 1985 Jun 30; 26(6):690-8. PubMed ID: 4031647 [Abstract] [Full Text] [Related] Page: [Next] [New Search]